tirzepatide depression and Risk | Mental Health Guide why does tirzepatide cause depression

At the level of individual MACE components, GLP-1 RAs also reduced CV mortality (by 13%, P = 0.016), nonfatal stroke (by 16%, P = 0.007), and nonfatal MI (by 9%, but statistically non-significant)

Smolen JS, Aletaha D, McInnes IB

A family history of obesity, diabetes, or cardiovascular disease may provide additional clinical context

Unlike earlier weight-loss medications, retatrutide is a triple receptor agonist , meaning it simultaneously activates three distinct hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors

Disclosure The authors declare no competing interests in this work